Sanara MedTech Inc. (SMTI)

Market Cap	300.63M
Revenue (ttm)	97.24M
Net Income (ttm)	-9.94M
Shares Out	8.90M
EPS (ttm)	-1.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,571
Open	35.03
Previous Close	35.28
Day's Range	33.00 - 35.03
52-Week Range	23.53 - 39.08
Beta	1.19
Analysts	Strong Buy
Price Target	50.00 (+48.06%)
Earnings Date	Nov 11, 2025

About SMTI

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a fre...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 141
• Stock Exchange: NASDAQ
• Ticker Symbol: SMTI
• Website: https://sanaramedtech.com

Financial Performance

In 2024, Sanara MedTech's revenue was $86.67 million, an increase of 33.36% compared to the previous year's $64.99 million. Losses were -$9.66 million, 124.6% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for SMTI stock is "Strong Buy." The 12-month stock price target is $50.0, which is an increase of 48.06% from the latest price.

Price Target

$50.0

(48.06% upside)

Analyst Consensus: Strong Buy